|
KMID : 0614620080510020111
|
|
Korean Journal of Gastroenterology
2008 Volume.51 No. 2 p.111 ~ p.118
|
|
|
Chemotherapy for Pancreatic Cancer
|
|
Kim Yong-Tae
|
|
|
Abstract
|
|
|
|
Chemotherapy is expected to play an important role in the treatment of pancreatic cancer because most of pancreatic cancers are being discovered at locally advanced or metastatic stages and recurrence rate is high even after the curative resection. Gemcitabine is a key agent for the first-line therapy of advanced pancreatic cancer. It can enhance the quality of life and prolong the survival of patients. Combination of erlotinib or capecitabine with gemcitabine showed a marginal survival benefit over single-agent gemcitabine. If patient`s performance state is good, gemcitabine-based platinum combination therapy showed overall survival benefit compared with gemcitabine monothrapy. If the first-line palliative chemotherapy fails, 5-FU, capcitabine, or tegafur with or without combination can be used as the second-line agents. Adjuvant chemotherapy using 5-FU or gemcitabine after curative resection has overall survival benefit. However, neoadjuvant chemotherapy has not been proven to be effective in the treatment of pancreatic cancer. (Korean J Gastroenterol 2008;51:111-118)
|
|
|
KEYWORD
|
|
|
Pancreatic cancer, Chemotherapy
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
   
|